This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment


Johansson, C., Ballard, C., Hansson, O., Palmqvist, S., Minthon, L., Aarsland, D., Londos, E.


International Journal Of Geriatric Psychiatry, Volume: 26, No.: 2, Pages.: 206-213

Year of Publication



Objective: This 30-week extension trial was a continuation of the first double-blind randomized controlled trial (RCT) to study memantine in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). The objective was to evaluate the presence of recurrence of symptoms upon drug withdrawal. Furthermore, the aim was to explore washout dynamics in order to inform clinical practice.; Methods: Patients were enrolled from psychiatric, memory and neurological outpatient clinics in Norway, Sweden and the UK. The trial comprised a 4-week washout period and a 26-week open-label treatment period. Outcome measures were presence of recurrence of symptom upon drug withdrawal, Clinical Global Impression of Change (CGIC) and modified motor Unified Parkinson’s Disease Rating Scale (UPDRS).; Results: recurrence of symptoms occurred more frequently (p=0.04) in patients receiving memantine (58%) than in patients receiving placebo (25%). There was a significant global deterioration (p=0.0003) during washout within the memantine group as measured by CGIC. The patients seemed to recover during the open-label treatment, however these findings were non-significant.; Conclusions: The findings inform clinical practice that any possible memantine-associated benefits might be rapidly lost after drug withdrawal. The magnitude of deterioration suggests a symptomatic rather than a disease-modifying effect of the drug. Open-label results should merely be considered inspiration for future trials.; Copyright © 2010 John Wiley & Sons, Ltd.

Bibtex Citation

@article{Johansson_2011, doi = {10.1002/gps.2516}, url = {}, year = 2011, month = {jan}, publisher = {Wiley-Blackwell}, volume = {26}, number = {2}, pages = {206--213}, author = {C. Johansson and C. Ballard and O. Hansson and S. Palmqvist and L. Minthon and D. Aarsland and E. Londos}, title = {Efficacy of memantine in {PDD} and {DLB}: an extension study including washout and open-label treatment}, journal = {Int. J. Geriat. Psychiatry} }


aged, aged, 80 and over, dopamine agents, double-blind method, drug therapy, female, great britain, humans, lewy body disease, male, memantine, norway, of, outcome assessment (health care), parkinson disease, post, psychiatric status rating scales, psychology, rate, recurrence, sweden, symptoms, therapeutic use, treatment

Countries of Study

Norway, Sweden, UK

Types of Dementia

Lewy-Body, Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes



Hospital Outpatient Care, Specialist Dementia Centre Care / Memory Clinic

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime